Yuki Izawa-Ishizawa
Overview
Explore the profile of Yuki Izawa-Ishizawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
762
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kono Y, Niimura T, Goda M, Ueta S, Kawada K, Miyata K, et al.
Cardiovasc Toxicol
. 2025 Feb;
25(3):498-506.
PMID: 39971867
Macrolides are associated with cardiovascular toxicity risk. However, data on their cardiovascular toxicity profiles beyond QT prolongation are limited, and differences in the profiles among various macrolide antibiotics remain unclear....
2.
Aizawa F, Kajimoto H, Okabayashi A, Moriyama D, Yagi K, Takahashi S, et al.
Neurochem Int
. 2024 Sep;
180:105863.
PMID: 39307458
Some therapeutic agents have been found to have effects beyond their primary indications. Peripheral neuropathy, a common side effect of chemotherapy, remains inadequately treated. Identifying additional properties of existing medications...
3.
Miyata K, Izawa-Ishizawa Y, Tsujinaka K, Nishi H, Itokazu S, Miyata T, et al.
Biomed Pharmacother
. 2024 Sep;
179:117418.
PMID: 39265233
Fluoroquinolones, which are widely used antibiotics, have been linked to aortic disease, which prompted an FDA warning in 2018. Recent reports have challenged the perception that fluoroquinolones pose a significant...
4.
Okamoto N, Yagi K, Imawaka S, Takaoka M, Aizawa F, Niimura T, et al.
Pharmacol Res Perspect
. 2024 Jul;
12(4):e1214.
PMID: 39031848
In the treatment of chronic myeloid leukemia (CML), resistance to BCR-ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to...
5.
Kawada K, Ishida T, Fukuda H, Hyohdoh Y, Kubo T, Hamada T, et al.
Front Cardiovasc Med
. 2024 Jun;
11:1377228.
PMID: 38883984
Introduction: Guideline-directed medical therapy with renin-angiotensin system (RAS) inhibitors and beta-blockers has improved the survival of patients with heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). However, it...
6.
Kawada K, Ishida T, Morisawa S, Jobu K, Higashi Y, Aizawa F, et al.
Front Pharmacol
. 2024 May;
15:1302055.
PMID: 38738173
Background: Exosome-like nanoparticles (ELNs) mediate interspecies intercellular communications and modulate gene expression. Hypothesis/purpose: In this study, we isolated and purified ELNs from the dried rhizome of Atractylodes lancea (Thunb.) DC....
7.
Miyata K, Izawa-Ishizawa Y, Niimura T, Hamano H, Aizawa F, Yagi K, et al.
J Med Invest
. 2024 May;
71(1.2):134-140.
PMID: 38735709
Aneurysm and arterial dissection have been reported as adverse drug events, associated with angiogenesis inhibitors and fluoroquinolones. Specifically, several cases of severe arterial disease following cGMP-specific phosphodiesterase type 5 (PDE5)...
8.
Hamano H, Zamami Y, Ushio S, Niimura T, Goda M, Izawa-Ishizawa Y, et al.
Yakugaku Zasshi
. 2024 Mar;
144(3):257-264.
PMID: 38432934
Cancer therapies have evolved considerably thereby substantially improving the survival of patients with cancer. However, cardiotoxicity, such as myocarditis and heart failure, induced by anticancer drugs, including immune checkpoint inhibitor(ICI)s...
9.
Tsujinaka K, Izawa-Ishizawa Y, Miyata K, Yoshioka T, Oomine K, Nishi H, et al.
Biomed Pharmacother
. 2023 Sep;
167:115504.
PMID: 37722188
Aortic dissection is an adverse event of angiogenesis inhibitors; however, the association between the drugs and aortic dissection is unclear. Therefore, we investigated if and how angiogenesis inhibitors increase the...
10.
Yoshioka T, Goda M, Kanda M, Itobayashi S, Sugimoto Y, Izawa-Ishizawa Y, et al.
Clin Transl Sci
. 2023 Sep;
16(11):2369-2381.
PMID: 37700528
Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods. Sodium valproic acid is a prophylactic drug candidate with...